Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 3—March 2008
Research

Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel

Isaac Levy*1, Galia Grisaru-Soen*12, Liat Lerner-Geva†, Eitan Kerem‡, Hana Blau§, Lea Bentur¶, Micha Aviram#, Joseph Rivlin**, Elie Picard††, Anita Lavy‡‡, Yakov Yahav*, and Galia Rahav*Comments to Author 
Author affiliations: *Sheba Medical Center, Tel Hashomer, Israel; †Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer, Israel; ‡Hadassah Hebrew University Hospital, Jerusalem, Israel; §Schneider Children’s Medical Center of Israel, Petah Tikva, Israel; ¶Rambam Medical Center, Haifa, Israel; #Soroka University Hospital, Beer Sheva, Israel; **Carmel Medical Center, Haifa, Israel; ††Shaare Zedek Medical Center, Jerusalem, Israel; ‡‡Mycobacterium Reference Laboratory of Israel, Tel Aviv, Israel; 1These authors contributed equally to this work.; 2Current affiliation: Dana Children’s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.;

Main Article

Table 3

Comparison of patients and controls in univariate and multivariate analyses*

Parameter Patients (n = 42) Controls (n = 144) p value Adjusted OR 95% CI
Age, y (mean ± SD) 24.2 ± 10.9 19.4 ± 10.0 0.014 1.03 0.99–1.09
Sex, F/M 18/24 56/88 0.64
No. sputum specimens (mean ± SD) 5.7 ± 4.8 2.4 ± 1.7 <0.0001 1.47 1.17–1.85
Hemoptysis 10 12 0.006 1.08 0.29–4.05
FEV1, L/s (mean ± SD) 56.7 ± 19.6 71.2 ± 21.8 0.0001 0.97 0.94–0.99
Pancreatic insufficiency 35 100 0.07
Sweat chloride, Meq/ L (mean ± SD) 73.1 ± 50.2 66.2 ± 48.3 0.43
Hospitalization, d (mean ± SD) 33.2 ± 37.5 18.4 ± 24.5 0.019 0.99 0.97–1.01
Administration of antimicrobial drugs, d (mean ± SD) 49.9 ± 78.7 14.7 ± 29.4 0.007 0.99 0.98–1.00
Azithromycin treatment 30 74 0.02 1.00 0.99–1.00
Azithromycin treatment, d (mean ± SD) 367.6 ± 302.7 221.9 ± 288.4 0.007 1.00 0.99–1.00
Ibuprofen treatment 5 2 0.001 4.72 0.60–36.85
Insulin treatment 4 13 0.92
Systemic steroids treatment 3 10 0.96
Inhaled steroids treatment 26 70 0.13
Pseudomonas aeruginosa 40 94 0.0005 0.76 0.32–1.79
Staphylococcus aureus 18 58 0.95
Aspergillus spp. 28 31 <0.0001 5.14 1.87–14.11
Allergic bronchopulmonary aspergillosis 3 3 0.10
Haemophillus influenza 3 24 0.13
Alcaligenes xylosoxidans 0 5 0.22
Klebsiella pneumoniae 3 4 0.17
Stenotrophomonas maltophilia 2 3 0.34

*OR, odds ratio; CI, confidence interval; SD, standard deviation; FEV1, forced expiratory volume in 1 s.

Main Article

1These authors contributed equally to this work.

2Current affiliation: Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external